NCT02259803已完成1 期
Relative Bioavailability of Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet Compared to Concomitant Use of Its Mono-components (i.e., Two Telmisartan 40 mg Tablets and Amlodipine 5 mg Tablet in Concomitant Use) Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 主要终点
- Maximum measured concentration of the analyte in plasma (Cmax)
研究概览
简要总结
Study to investigate the relative bioavailability of fixed-dose combination tablet vs.
mono-components of telmisartan and amlodipine
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 35 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males according to the following criteria:
- •Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate and body temperature), 12-lead ECG, clinical laboratory tests, no finding of clinical relevance, no evidence of a clinically relevant concomitant disease
- •Age ≥20 and Age ≤35 years
- •Body weight ≥50 kg
- •BMI ≥17.6 and BMI ≤26.4 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice
排除标准
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •Chronic or relevant acute infections
- •Any clinical relevant findings of the laboratory test deviating from normal
- •Positive result for hepatitis B antigen, anti hepatitis C virus anti bodies, syphilitic test or HIV test
- •Surgery of gastrointestinal tract (except appendectomy)
- •History of relevant orthostatic hypotension (mean standing systolic blood pressure (SBP) varies by ≥20 mmHg from mean supine SBP or mean standing diastolic blood pressure (DBP) varies by ≥10 mmHg from mean supine DBP), fainting spells or blackouts
- •History of hepatic dysfunction (e.g. biliary cirrhosis, cholestasis)
- •History of serious renal dysfunction
- •History of bilateral renal artery stenosis or renal artery stenosis in a solitary kidney
- •History of cerebrovascular disorder
- •History of hyperkalemia
- •Known hypersensitivity to any component of the formulation, or to any other angiotensin II receptor blockers, angiotensin converting enzyme or dihydropyridine
- •Intake of drugs with a long half-life (≥24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 7 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within 4 months or 6 half-lives of the investigational drug prior to administration
- •Smoker (≥20 cigarettes/day)
- •Alcohol abuse (60 g or more ethanol/day: ex. 3 middle-sized bottles of beer, 3 gous (equivalent to 540 mL) of sake)
- •Blood donation (more than 100 mL within 4 weeks prior to administration or during the trial)
- •Excessive physical activities (within 1 week prior to administration or during the trial)
- •Intake of alcohol within 2 days prior to administration
- •Inability to comply with dietary regimen of study centre
- •Intake of any drugs/supplements with ingredient of hypericum perforatum or citrus fruits (e.g. grapefruits, Sevilla orange) within 5 days prior to administration
- •Inability to refrain from smoking on trial days
- •Any other volunteers whom, the principal investigator or sub investigator would not allow to participate in this study
研究组 & 干预措施
Telmisartan/amlodipine fixed-dose combination
Experimental
干预措施: Telmisartan/amlodipine fixed-dose combination (FDC) tablet (Drug)
Telmisartan and amlodipine mono-components
Active Comparator
干预措施: Telmisartan (Drug)
Telmisartan and amlodipine mono-components
Active Comparator
干预措施: Amlodipine (Drug)
结局指标
主要结局
Maximum measured concentration of the analyte in plasma (Cmax)
时间窗: up to 144 hours after administration of study drug
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
时间窗: up to 144 hours after administration of study drug
次要结局
- Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)(up to 144 hours after administration of study drug)
- Terminal rate constant of the analyte in plasma (λz)(up to 144 hours after administration of study drug)
- Time from administration to the maximum concentration of the analyte in plasma (tmax)(up to 144 hours after administration of study drug)
- Terminal rate constant of the analyte in plasma (t1/2)(up to 144 hours after administration of study drug)
- Mean residence time of the analyte in the body after po administration (MRTpo)(up to 144 hours after administration of study drug)
- Number of subjects with adverse events(up to 56 days)
研究者
相似试验
已完成
1 期
Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male VolunteersHealthyNCT02259790Boehringer Ingelheim30
已完成
1 期
Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy SubjectsHealthyNCT02176512Boehringer Ingelheim20
已完成
1 期
Relative Oral Bioavailability of Telmisartan / Hydrochlorothiazide (HCTZ) Fixed Dose Combination (FDC) Compared With Its Monocomponents in Healthy SubjectsHealthyNCT02187523Boehringer Ingelheim32
已完成
1 期
Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male SubjectsHealthyNCT02262793Boehringer Ingelheim24
已完成
1 期
Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female SubjectsHealthyNCT02262650Boehringer Ingelheim24